IDL Diagnostics AB (publ) (STO:IDLDX)
Sweden · Delayed Price · Currency is SEK 0.3500
-0.0140 (-3.85%)
Mar 4, 2026, 5:01 PM CET
IDL Diagnostics AB Company Description
IDL Diagnostics AB (publ), a vitro diagnostics company, manufactures and sells IVD tests for oncological and bacterial diseases in Sweden.
It offers UBC Rapid, a point-of-care test for diagnosis and monitoring of bladder cancer; AroCell TK 210 ELISA, a biomarker for tumor cells; and TUBEX TF, a vitro diagnostic test for detection of acute typhoid fever.
The company was formerly known as AroCell AB (publ) and changed its name to IDL Diagnostics AB (publ) in May 2025.
IDL Diagnostics AB (publ) was incorporated in 2000 and is based in Stockholm, Sweden.
IDL Diagnostics AB (publ)
| Country | Sweden |
| Founded | 2000 |
| Industry | Diagnostics & Research |
| Sector | Healthcare |
| Employees | 20 |
| CEO | Anders Hultman |
Contact Details
Address: KarlsbodavAegen 39 Stockholm, 168 67 Sweden | |
| Phone | 46 87 99 67 50 |
| Website | idldiagnostics.com |
Stock Details
| Ticker Symbol | IDLDX |
| Exchange | Nasdaq Stockholm |
| Fiscal Year | January - December |
| Reporting Currency | SEK |
| ISIN Number | SE0003883990 |
| SIC Code | 2835 |
Key Executives
| Name | Position |
|---|---|
| Anders Hultman B.Sc. | Chief Executive Officer |
| Ellen Dittberner | Chief Finance Officer |
| Maria Sundberg | Chief Operations Officer |
| Leyla Ali Dholey | Chief Scientific Officer |
| Gustav Sten | Chief Marketing Officer |
| Jocelyn Akerberg | Chief Quality Officer |